Cargando…
Treatment satisfaction, adherence and behavioral assessment in patients de – escalating from natalizumab to interferon beta
BACKGROUND: De-escalating natalizumab (NTZ) to interferon beta 1b (IFN B 1B) is a possible treatment option in multiple sclerosis (MS) patients interrupting NTZ because of increased risk of progressive multifocal leukoencephalopathy (PML). The aim of this study was to evaluate satisfaction and adher...
Autores principales: | Zecca, Chiara, Riccitelli, Gianna C, Calabrese, Pasquale, Pravatà, Emanuele, Candrian, Ursula, Guttmann, Charles RG, Gobbi, Claudio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3940251/ https://www.ncbi.nlm.nih.gov/pubmed/24576156 http://dx.doi.org/10.1186/1471-2377-14-38 |
Ejemplares similares
-
Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial
por: Gobbi, Claudio, et al.
Publicado: (2013) -
Migraine in Multiple Sclerosis Patients Affects Functional Connectivity of the Brain Circuitry Involved in Pain Processing
por: Pravatà, Emanuele, et al.
Publicado: (2021) -
Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients
por: Zecca, Chiara, et al.
Publicado: (2019) -
Sleep-Related Breathing Disorders in Multiple Sclerosis: Prevalence, Features and Associated Factors
por: Sparasci, Davide, et al.
Publicado: (2022) -
Improvement of interferon-beta related skin reactions after diluent halving: first experience of five patients
por: Zecca, Chiara, et al.
Publicado: (2012)